

# FINAL - October 20, 2021

## MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

October 20-21, 2021

### PRESIDER/PRESENTER(s)

#### Wednesday, October 20, 2021

10:00	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:30	<b>Agency Updates</b>	
10:45	<b>Pneumococcal Vaccines</b>	
	Introduction	Dr. Katherine Poehling (ACIP, WG Chair)
	Considerations for age-based and risk-based use of PCV15/PCV20 among adults and proposed policy options	Dr. Miwako Kobayashi (CDC/NCIRD)
	Discussion	Dr. Miwako Kobayashi (CDC/NCIRD)
12:45	<b>Break</b>	
1:15	<b>Zoster Vaccines</b>	
	Introduction	Dr. Camille Kotton (ACIP, WG Chair)
	Work group interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options	Dr. Tara Anderson (CDC/NCIRD)
	Discussion	Dr. Tara Anderson (CDC/NCIRD)
2:15	<b>Break</b>	
2:30	<b>Influenza Vaccines</b>	
	Introduction	Dr. Keipp Talbot (ACIP, WG Chair)
	Phase II safety and immunogenicity study of the coadministration of Fluzone® High-Dose Quadrivalent Influenza Vaccine and a third dose of Change in Age Indication for Flucelvax Quadrivalent	Dr. Ruvim Izikson (Sanofi Pasteur)
		Dr. Lisa Grohskopf (CDC/NCIRD)
3:30	<b>Break</b>	
3:45	<b>Public Comment</b>	
4:15	<b>Break</b>	
4:20	<b>Votes</b>	
	Pneumococcal Vote	Dr. Miwako Kobayashi (CDC/NCIRD)
	Zoster Vote	Dr. Tara Anderson (CDC/NCIRD)
5:00	<b>Adjourn</b>	

#### Thursday, October 21, 2021

10:00	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:15	<b>Coronavirus Disease 2019 (COVID-19) Vaccines</b>	
	Introduction	Dr. Matthew Daley (ACIP, WG Chair)
	Moderna- Booster dose data	Dr. Jacqueline Miller (Moderna)
	Janssen- Booster dose data	Dr. Penny Heaton & Dr. Macaya Douoguih (Janssen)
	National Institutes of Health, Mix and Match booster study	Dr. Robert Atmar (Baylor College of Medicine)
11:45	<b>Break</b>	
12:00	<b>Public comment</b>	
12:40	v-safe and VAERS - third dose and simultaneous vaccination	Dr. Anne Hause (CDC/NCEZID)
	COVID-19 Vaccine Safety Updates	Dr. Tom Shimbukuro (CDC/NCEZID)
	Myocarditis- VAERS	Dr. John Su (CDC/NCEZID)
	Myocarditis- VSD	Dr. Nicky Klein (KPNC)
	VaST Assessment	Dr. Keipp Talbit (VaST Chair)
2:05	<b>Break</b>	
2:20	COVID-19 vaccine effectiveness, primary series	Dr. Jefferson Jones (CDC/NCIRD)
	Evidence to Recommendations	Dr. Kathleen Dooling (CDC/NCIRD)
	Clinical considerations	Dr. Sujana Reddy (CDC/NCEZID)
	Policy Questions	Dr. Kathleen Dooling (CDC/NCIRD)
4:20	<b>Break</b>	
	<b>Vote</b>	
5:00	<b>Adjourn</b>	

**Acronyms**

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
RZV	Recombinant Zoster Vaccine
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness